Latest Cancer News
Over about six years of follow-up, women diagnosed with breast cancer at age 50 or younger had twice the risk of developing either osteoporosis or a severe bone-loss condition called osteopenia than those without cancer.
The risk was up to four times higher among breast cancer survivors who had undergone treatments that block estrogen production, according to the study.
"These findings show that even younger women have a relatively high risk of bone loss with standard breast cancer treatments, and in many cases we saw this bone loss occurring in just a few years," said senior study author Dr. Kala Visvanathan. She's a professor in the department of epidemiology at Johns Hopkins Bloomberg School of Public Health in Baltimore.
"These results suggest that we should monitor even young breast cancer patients for bone loss during and after therapy," Visvanathan said in a Hopkins news release.
Previous research has shown that older breast cancer survivors are at increased risk of bone loss.
This study found that the risk of bone loss was particularly high after certain types of breast cancer treatment. Women receiving the standard combination of chemotherapy plus hormonal therapy had a 2.7 times increased risk of osteopenia and osteoporosis compared to those without cancer.
Chemotherapy plus tamoxifen was associated with a 2.5 times higher risk, but not tamoxifen alone. Aromatase inhibitors, which reduce estrogen production, were associated with a 2.7 times higher risk for bone loss alone, and a 3.8 times higher risk when combined with chemotherapy, the study found.
The increased risk of bone loss in breast cancer survivors was evident even when women with premature menopause were not included in the analysis.
"There seems to be an effect of cancer treatment on bone health that works independently of menopause -- perhaps by directly inhibiting bone formation," Visvanathan said.
The study was published recently in the journal Breast Cancer Research.
-- Robert Preidt
Copyright © 2018 HealthDay. All rights reserved.